PDF(Pubmed)
Abstract：
UNASSIGNED: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the digestive tract, with surgery and tyrosine kinase inhibitor (TKI) therapy being its main treatment options. However, long-term use of TKIs may lead to drug resistance, which poses a challenge to the long-term survival of patients. We explore a new combination of transcatheter arterial chemoembolization (TACE) with TKI for liver metastasis (LM) of GIST to provide patients with more treatment options and better prognosis.
UNASSIGNED: This case report describes the application of 6 TACE sessions in the 12-year treatment of multiple LM from small intestinal stromal tumors that were resistant to multiple TKIs. The patient, a 58-year-old male, underwent multiple surgical resections and drug therapies for the LM after a primary small bowel stromal tumor had been identified and resected following an onset symptom of abdominal pain in February 2012. Despite the challenges of drug resistance and economic considerations, 6 TACE sessions effectively controlled the tumor, winning valuable treatment time for the patient. Since the initiation of ripretinib 150 mg once daily in July 2023, the tumor has continued to shrink, with satisfactory drug tolerance.
UNASSIGNED: For GIST patients with LM, TACE combined with various TKI drugs could effectively control intrahepatic tumor progression and prolong patient survival. During six TACE sessions, the patient experienced liver tumor rupture and massive bleeding. However, the bleeding was completely stopped by embolization, and the lesion shrank. Our findings provide a new perspective and treatment strategy for the treatment of LM from GIST.
UNASSIGNED: This case report describes the application of 6 TACE sessions in the 12-year treatment of multiple LM from small intestinal stromal tumors that were resistant to multiple TKIs. The patient, a 58-year-old male, underwent multiple surgical resections and drug therapies for the LM after a primary small bowel stromal tumor had been identified and resected following an onset symptom of abdominal pain in February 2012. Despite the challenges of drug resistance and economic considerations, 6 TACE sessions effectively controlled the tumor, winning valuable treatment time for the patient. Since the initiation of ripretinib 150 mg once daily in July 2023, the tumor has continued to shrink, with satisfactory drug tolerance.
UNASSIGNED: For GIST patients with LM, TACE combined with various TKI drugs could effectively control intrahepatic tumor progression and prolong patient survival. During six TACE sessions, the patient experienced liver tumor rupture and massive bleeding. However, the bleeding was completely stopped by embolization, and the lesion shrank. Our findings provide a new perspective and treatment strategy for the treatment of LM from GIST.
摘要：
■胃肠道间质瘤（GIST）是最常见的消化道间质瘤，手术和酪氨酸激酶抑制剂（TKI）治疗是其主要治疗选择。然而,长期使用TKIs可能导致耐药性，这对患者的长期生存提出了挑战。我们探索经导管动脉化疗栓塞（TACE）与TKI治疗GIST肝转移（LM）的新组合，为患者提供更多的治疗选择和更好的预后。
■该病例报告描述了6次TACE治疗在对多种TKIs耐药的小肠间质瘤的多种LM的12年治疗中的应用。病人,一个58岁的男性,在2012年2月发现原发性小肠间质瘤并在出现腹痛症状后切除后,对LM进行了多次手术切除和药物治疗.尽管存在耐药性和经济考虑的挑战，6次TACE治疗有效控制了肿瘤，为患者赢得宝贵的治疗时间。自2023年7月开始每天一次150毫克利普替尼以来，肿瘤一直在缩小，具有令人满意的药物耐受性。
■对于患有LM的GIST患者，TACE联合多种TKI药物可有效控制肝内肿瘤进展，延长患者生存期。在六次TACE会议期间，患者出现肝肿瘤破裂和大出血。然而,通过栓塞完全止血,病变缩小了.我们的发现为GIST中LM的治疗提供了新的视角和治疗策略。
■该病例报告描述了6次TACE治疗在对多种TKIs耐药的小肠间质瘤的多种LM的12年治疗中的应用。病人,一个58岁的男性,在2012年2月发现原发性小肠间质瘤并在出现腹痛症状后切除后,对LM进行了多次手术切除和药物治疗.尽管存在耐药性和经济考虑的挑战，6次TACE治疗有效控制了肿瘤，为患者赢得宝贵的治疗时间。自2023年7月开始每天一次150毫克利普替尼以来，肿瘤一直在缩小，具有令人满意的药物耐受性。
■对于患有LM的GIST患者，TACE联合多种TKI药物可有效控制肝内肿瘤进展，延长患者生存期。在六次TACE会议期间，患者出现肝肿瘤破裂和大出血。然而,通过栓塞完全止血,病变缩小了.我们的发现为GIST中LM的治疗提供了新的视角和治疗策略。
